Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
679results about How to "Reduced expression level" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods for genetic control of insect infestations in plants and compositions thereof
ActiveUS20070124836A1Inhibit expressionReduced expression levelSugar derivativesClimate change adaptationBiotechnologyDouble strand
The present invention relates to control of pest infestation by inhibiting one or more biological functions. The invention provides methods and compositions for such control. By feeding one or more recombinant double stranded RNA molecules provided by the invention to the pest, a reduction in pest infestation is obtained through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.
Owner:MONSANTO TECH LLC
Methods for genetic control of insect infestations in plants and compositions thereof
ActiveUS7943819B2Reduced expression levelLow effective doseSugar derivativesClimate change adaptationGMO PlantsDouble stranded rna
Owner:MONSANTO TECH LLC
MicroRna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
ActiveUS20080306006A1Inhibiting tumorigenesisPrevent proliferationOrganic active ingredientsPeptide/protein ingredientsMicroRNASolid cancer
The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provide methods of identifying inhibitors of tumorigenesis.
Owner:THE OHIO STATE UNIV RES FOUND
AAV vectors produced in insect cells
ActiveUS8163543B2Improve stabilityReduced expression levelAnimal cellsGenetic material ingredientsNucleotideViral vector
The present invention relates to the production of adeno-associated viral vectors in insect cells. The insect cells therefore comprise a first nucleotide sequence encoding the adeno-associated virus (AAV) capsid proteins, whereby the initiation codon for translation of the AAV VP1 capsid protein is a non-ATG, suboptimal initiation codon. The insect cell further comprises a second nucleotide sequence comprising at least one AAV inverted terminal repeat (ITR) nucleotide sequence; a third nucleotide sequence comprising a Rep52 or a Rep40 coding sequence operably linked to expression control sequences for expression in an insect cell; and, a fourth nucleotide sequence comprising a Rep78 or a Rep68 coding sequence operably linked to expression control sequences for expression in an insect cell. The invention further relates to adeno-associated viral vectors with an altered ratio of the viral capsid proteins that provides improved infectivity of the viral particles.
Owner:UNIQURE IP BV
Parvoviral capsid with incorporated gly-ala repeat region
InactiveUS20110171262A1Improve stabilityReduced expression levelBiocideAntibody mimetics/scaffoldsNucleic acid sequencingCapsid
Parvoviral capsid with incorporated Gly-Ala repeat region The present invention provides a nucleic acid construct comprising a nucleic acid sequence encoding a parvoviral VP1, VP2 and VP3 capsid proteins comprising an immuno evasion repeat sequence. In addition, the present invention provides a cell comprising such construct, a parvoviral virion comprising a capsid protein that comprises an immune evasion repeat sequence, use of that parvoviral virion in gene therapy and a pharmaceutical composition comprising such parvoviral virion.
Owner:AMSTERDAM MOLECULAR THERAPEUTICS
Disease therapy with chimeric antigen receptor (CAR) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
InactiveUS20160361360A1Maintain self-toleranceModulate durationAntibacterial agentsPeptide/protein ingredientsAutoimmune conditionDebulking Procedure
The present invention concerns CAR, CAR-T and CAR-NK constructs, preferably comprising a scFv antibody fragment against a disease-associated antigen or a hapten. More preferably, the antigen is a TAA, such as Trop-2. The constructs may be administered to a subject with a disease, such as cancer, autoimmune disease, or immune dysfunction disease, to induce an immune response against disease-associated cells. Where the constructs bind to a hapten, the subject is first treated with a hapten-conjugated antibody that binds to a disease associated antigen. Therapy may be supplemented by other treatments, such as debulking procedures (e.g., surgery, chemotherapy, radiation therapy) or coadministration of other agents. More preferably, administration of the construct is preceded by predosing with an unconjugated antibody that binds to the same disease-associated antigen. Most preferably, an antibody against CD74 or HLA-DR is administered to reduce systemic immunotoxicity induced by the constructs.
Owner:IMMUNOMEDICS INC
Method for the analysis of differential expression in colorectal cancer
InactiveUS20080286801A1Reduced expression levelReduce expressionMicrobiological testing/measurementAntineoplastic agentsGene expression levelGene
A method for the analysis of differential expression in colorectal cancer based on the variation in the expression levels of genes encoding for proteins forming part of the condensin complex or associated proteins that occurs in patients with the disease and that can be used as markers for the diagnosis of the cancers, as well as for the prevention and treatment thereof.
Owner:ORYZON GENOMICS SA
Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
ActiveUS8512981B2Improve stabilityReduced expression levelVirus peptidesNucleic acid vectorStart codonNucleotide
The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
Owner:AMSTERDAM MOLECULAR THERAPEUTICS +1
Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
InactiveUS7494775B2Reduced expression levelCompound screeningApoptosis detectionOncologyOvarian cancer
The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Bi-Functional Short-Hairpin RNA (Bi-shRNA) Specific for Single-Nucleotide KRAS Mutations
ActiveUS20130302407A1Reduce expressionReduced expression levelOrganic active ingredientsSpecial deliveryRNA-induced silencing complexNucleotide
The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.
Owner:GRADALIS
Baculoviral vectors comprising repeated coding sequences with differential codon biases
ActiveUS8697417B2Improve stabilityReduced expression levelAnimal cellsSugar derivativesViral vectorParvovirus
The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
Owner:UNIQURE IP BV
Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav
ActiveUS20130296532A1Improve stabilityReduced expression levelVirus peptidesNucleic acid vectorNucleotideCapsid
The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
Owner:UNIQURE IP BV
Recombinant expression of human desmocyte growth factor-21
ActiveCN101250547AReduce sensitivityPromote regionalizationBacteriaPeptide/protein ingredientsEscherichia coliOrganism
The invention relates to a method for recombinating and expressing human fibroblast growth factors, which comprises following steps: fusing an FGF-21 gene and a molecular chaperone Sumo sequence, building a new prokaryotic expression vector, transforming escherichia coli, thereby building engineering bacteria, and obtaining the FGF-21 through culturing the engineering bacteria and inducing expression. The method of the invention can promote soluble expression of protein, which is beneficial for folding recombined protein correctly and is convenient for separating and purifying the protein. Activity detection proves that the recombined protein which is obtained has comparatively high biological activity and the bioactivity is equivalent to the bioactivity of FGF21standard products.
Owner:杭州生长因子医药科技有限公司
Kidney Toxicity Biomarkers
InactiveUS20090298073A1Reduced expression levelSugar derivativesPeptide/protein ingredientsLead compoundMedicine
Owner:MERCK SHARP & DOHME CORP
Directed evolution of microorganisms
Owner:SCHELLENBERGER VOLKER +2
Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
InactiveUS20060068425A1Reduced expression levelHigh expressionCompound screeningTumor rejection antigen precursorsOncologyHuman prostate
The invention relates to newly discovered nucleic acid molecules and proteins associated with prostate cancer including pre-malignant conditions. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human prostate cancers are provided.
Owner:MILLENNIUM PHARMA INC
Tetracycline repressor regulated oncolytic viruses
The present invention is directed oncolytic Herpes simplex-l viruses whose replication is controlled using a tetracycline operator / repressor system. The invention also includes DNA sequences used in making the viruses and methods in which these viruses are used in the treatment of cancer patients with solid tumors.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Use of hmgb1 for the activation of dendritic cells
InactiveUS20040242481A1Reduced expression levelHigh expressionUltrasonic/sonic/infrasonic diagnosticsBiocideDendritic cellNucleotide
Use of the protein HMGB1 or a variant or fragment thereof or a polynucleotide encoding therefor for inducing the activation of an antigen presenting cell (APC).
Owner:FOND CENT SAN RAFFAELLE DEL MONTE TABOR
Uses of monoclonal antibody 8h9
ActiveUS20050169932A1Reduced expression levelInhibit expressionCompounds screening/testingAntibody mimetics/scaffoldsAntigenDrug
This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.
Owner:SLOAN KETTERING INST FOR CANCER RES
Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
InactiveUS7125663B2Reduced expression levelImmunoglobulins against cell receptors/antigens/surface-determinantsTissue cultureOncologyGene
The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.
Owner:MILLENNIUM PHARMA INC
Cell lines for production of replication-defective adenovirus
ActiveUS20060270041A1Promote infectionIncrease productionSugar derivativesGenetically modified cellsPolymerase LDefective virus
The present invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. The present invention also provides cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B and E2B polymerase functions. The invention provides particular cell lines that complement E1A function by insertion of an E1A sequence containing mutations in the 243R and 289R proteins and an E1B sequence comprising the E1B-55K gene. Production yields in the resulting producer cell lines, designated SL0003 and SL0006, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus (“RCA”).
Owner:CANJI
Identification of genetic alterations that modulate drug sensitivity in cancer treatments
InactiveUS20080242622A1Improve efficiencyModulate cancer cells' sensitivity to an anti-cancer drugBiocideLibrary screeningCancer cellDrugs sensitivity
Owner:COLD SPRING HARBOR LAB INC
Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
ActiveUS8828718B2Reduced expression levelVectorsGenetic material ingredientsBiotechnologyBinding site
The present invention relates to a gene transfer vector (GTV) and in particular to an integrating gene transfer vector (IGTV), which comprises at least one genetic insulator element (GIE), wherein the each comprises at least two copies of an element selected from the group consisting of: a CTF binding site; a first CTCF binding site and a second CTCF binding site, wherein the first and the second CTCF binding sites are derived from the regulatory sequences of different genes.
Owner:CENT NAT DE LA RECHERCHE SCI
Methods for identifying drug combinations for the treatment of proliferative diseases
InactiveUS20050100508A1Good effectToxic reductionOrganic active ingredientsGenetic material ingredientsCombination therapyCancer research
The invention features methods for identifying new combination therapies for the treatment of cancer and other proliferative diseases.
Owner:COMBINATIORX
Porphobilinogen deaminase gene therapy
InactiveUS8697665B2Improve stabilityReduced expression levelBiocideNervous disorderNucleotideDNA construct
The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.
Owner:PROYECTO DE BIOMEDICINA CIMA +1
Combinations for the treatment of proliferative diseases
InactiveUS20050158320A1Good effectToxic reductionGenetic material ingredientsBiological material analysisCombination therapyCancer research
Owner:COMBINATORX
Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav
ActiveUS20090191588A1Improve stabilityReduced expression levelAnimal cellsSugar derivativesStart codonNucleotide
The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
Owner:AMSTERDAM MOLECULAR THERAPEUTICS +1
Monoclonal Antibody Capable of Binding to Anexelekto, and Use Thereof
InactiveUS20110044984A1Reduced expression levelAntibody mimetics/scaffoldsAntibody ingredientsSpecific functionPhosphorylation
The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity.
Owner:CHUGAI PHARMA CO LTD
Apoptosis-Inducing Agent for Prostate Cancer Cells
InactiveUS20090005538A1Reduced expression levelInhibit prostate cancerPeptide/protein ingredientsDepsipeptidesProstate cancer cellLymphatic Spread
According to the present invention, an apoptosis-inducing agent for prostate cancer comprising REIC / Dkk-3 DNA or an REIC / Dkk-3 protein, and a therapeutic agent for prostate cancer and an agent for inhibiting prostate cancer metastasis that comprise such apoptosis-inducing agent are provided.An apoptosis-inducing agent for prostate cancer, comprising, as an active ingredient, an REIC / Dkk-3 protein (a) or (b) or REIC / Dkk-3 DNA (c) or (d):(a) a protein consisting of the amino acid sequence represented by SEQ ID NO: 2;(b) a protein consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 by substitution or deletion of 1 or more amino acids;(c) DNA consisting of the nucleotide sequence represented by SEQ ID NO: 1; or(d) DNA that hybridizes under stringent conditions to DNA consisting of a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 1 and encodes a protein having apoptosis activity; anda therapeutic agent for prostate cancer comprising such apoptosis-inducing agent are provided
Owner:KUMON HIROMI +3
Compositions Comprising Actinidia and Methods of Use Thereof
InactiveUS20100111927A1Regulate the amount of an antibody isotypeLower Level RequirementsBiocideAntipyreticDiseaseEnvironmental health
Disclosed are novel preparations of Actinidia, and particularly species of hardy kiwifruit, as well as compositions comprising the same. Also disclosed is the use of these preparations of Actinidia to prevent and / or treat a variety of diseases in which regulation of the immune response is effective, including both allergic and non-allergic inflammatory disease, viral infection, and cancer. Methods related to making and using these compositions are also described.
Owner:KIM SUNYOUNG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com